0000000000123998

AUTHOR

Alinta Hegmane

showing 2 related works from this author

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

2018

We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia (Cl…

0301 basic medicineCancer ResearchChemotherapymedicine.medical_specialtySurrogate endpointColorectal cancerbusiness.industrymedicine.medical_treatmentHazard ratioCancerArticlesNeutropeniamedicine.disease03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologyRefractorychemistry030220 oncology & carcinogenesisInternal medicinemedicinebusinessTipiracilMolecular and Clinical Oncology
researchProduct

How do international gastric cancer prevention guidelines influence clinical practice globally?

2020

Clinical guidelines recommend particular approaches, including 'screen-and-treat' strategy for Helicobacter pylori, to prevent gastric cancer. However, little of this is implemented in clinical practice. The aim of the study was to identify barriers to implementation of international guidelines. A web-based questionnaire distributed globally to specialists in the field. Altogether 886 responses from 75 countries were received. Of the responders, 570 (64%) were men of mean age 47 years. There were 606 gastroenterologists and 65 epidemiologists among the responders. Altogether, 79.8% of the responders disagreed that the burden of gastric cancer is a diminishing problem. 'Screen-and-treat' str…

AdultMaleCancer Researchmedicine.medical_specialtyEpidemiologyPopulationMEDLINEHelicobacter Infections03 medical and health sciencesYoung Adult0302 clinical medicineSDG 3 - Good Health and Well-beingStomach NeoplasmsSurveys and QuestionnairesmedicineHumans030212 general & internal medicinePractice Patterns Physicians'educationEarly Detection of CancerAgedAged 80 and overeducation.field_of_studybiologyHelicobacter pyloribusiness.industryGastric cancer preventionUpper endoscopyPublic Health Environmental and Occupational HealthCancerInternational AgenciesHelicobacter pyloriMiddle Agedmedicine.diseasebiology.organism_classificationPrognosis3. Good healthClinical PracticeVaccinationSurvival RateOncology030220 oncology & carcinogenesisFamily medicinePractice Guidelines as Topic/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalebusinessEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
researchProduct